Trials / Completed
CompletedNCT00922428
PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders: A Non-interventional Observational Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,389 (actual)
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.
Detailed description
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms. Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management in relation to the Summary of Product Characteristics (SmPC).
Conditions
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2009-06-17
- Last updated
- 2015-05-04
- Results posted
- 2015-05-04
Source: ClinicalTrials.gov record NCT00922428. Inclusion in this directory is not an endorsement.